## Does China's 2028 BCI Standards Push Signal the Start of a Global Patent War?

**China's Ministry of Industry and Information Technology (MIIT) released draft guidelines on August 25, 2026 targeting more than 40 [brain-computer interface](https://bciintel.com/glossary/brain-computer-interface) standards and participation in more than 10 international standards by 2028 — a timeline that compresses what would normally be a decade of standards development into roughly two years.** The same release package covered humanoid robots, targeting at least 100 key standards covering more than 200 enterprises. The BCI framework targets implementation across more than 100 enterprises. Both documents were opened for public comment simultaneously, signaling coordinated industrial policy rather than organic technical consensus.

This is not primarily a safety story or a clinical story. It is a strategic one. Standards bodies are where technical routes get frozen into infrastructure — and once a patented technical solution is embedded in a mandatory standard, it becomes a standard essential patent (SEP), extracting royalties across an entire industrial chain for years. China has watched this dynamic play out in mobile communications and Wi-Fi. Now it is moving early in BCI, before the global technical architecture has consolidated.

For Western BCI developers — from intracortical array makers to [ECoG](https://bciintel.com/glossary/ecog)-based platforms — the window to shape international standards is narrowing.

---

## What the MIIT Draft Actually Covers

The BCI standard system as outlined in the draft organizes requirements across seven domains:

1. **Basic commonality** — foundational definitions, terminology, classification
2. **Hardware** — electrode arrays, signal acquisition modules, implant materials
3. **Software and algorithms** — signal decoding, spike sorting, codec frameworks
4. **Data and communication** — neural signal data formats, transmission protocols, interoperability
5. **Products and systems** — integrated device evaluation, performance benchmarking
6. **Industry applications** — clinical, consumer, and assistive use cases
7. **Safety and governance** — biocompatibility, cybersecurity, clinical risk classification

The document explicitly names interface compatibility, data interoperability, capability evaluation, and risk control as primary goals — in other words, the exact technical layers where proprietary solutions from companies like [Neuralink Corp](https://bciintel.com/companies/neuralink), [Synchron](https://bciintel.com/companies/synchron), [Precision Neuroscience](https://bciintel.com/companies/precision-neuroscience), and [Blackrock Neurotech](https://bciintel.com/companies/blackrock-neurotech) currently differ most from one another.

The source article notes that a brain signal acquisition device from one enterprise may currently be incompatible with analysis software from another — a fragmentation problem that genuine standardization would solve, but that also creates an enormous first-mover advantage for whichever company's architecture gets encoded into the standard.

---

## The SEP Mechanism: Why Standards Are Worth Fighting Over

Standard essential patents are not a novel concept, but their application to neural interfaces is new territory. The logic is straightforward: when a standard mandates a specific technical implementation — a particular data format for neural signals, a communication protocol between implant and decoder, a method for evaluating electrode array performance — and that implementation is covered by an existing patent, every company that builds to the standard must license that patent. The standard creator does not need to win in court. They win at the drafting table.

The 36Kr analysis draws a direct line from telecom SEP battles to what may be coming in BCI. In mobile communications, the fights over royalty rates, licensing tiers, and injunction relief have persisted for decades and involve some of the largest litigation budgets in technology. BCI is a smaller market today, but the clinical necessity of interoperability — imagine a hospital needing its neural signal acquisition hardware to communicate with multiple decoding software vendors — makes SEP exposure structurally similar.

For neural interface developers, the data format layer is particularly vulnerable. If China's national standard specifies how raw electrode signals are encoded, compressed, and transmitted, any company holding patents on that encoding scheme gains leverage over every other participant in markets that adopt the standard — including, potentially, international markets if China succeeds in its goal of leading or participating in more than 10 international standards.

---

## What This Means for Western BCI Developers

The competitive implication is asymmetric. Chinese BCI companies — including domestic players such as [Neuracle Medical Technology](https://bciintel.com/companies/neuracle-medical) — will have direct input into the MIIT consultation process. US and European companies generally do not. The international standards bodies where Western companies have more influence — ISO, IEC, IEEE — move considerably slower than a two-year national mandate.

This does not mean Chinese standards automatically become global standards. But it does mean:

- **China's domestic market of more than 100 BCI enterprises will coalesce around a defined technical architecture by 2028.** Foreign companies wanting to sell into China will need to conform.
- **If China's representatives push these frameworks into ISO/IEC working groups**, they arrive with a fully developed national standard as their negotiating position — a significant procedural advantage.
- **Patent filings around the technical choices embedded in the draft** — signal acquisition protocols, codec methods, safety classification schemes — are likely already accelerating. The article's core thesis is that the next patent war begins not in court, but at standardization meetings, and that process is already underway.

For companies like [Precision Neuroscience](https://bciintel.com/companies/precision-neuroscience) or [Synchron](https://bciintel.com/companies/synchron) with international ambitions, the question is whether their current technical architectures are defensible under a Chinese-influenced international standard, or whether they would face royalty exposure or redesign costs.

The intersection of neural interface standards and humanoid robot control architectures is also worth watching. As BCI technology moves toward applications in robotic prosthetics and direct neural control of humanoid platforms, the standards governing both domains will increasingly overlap. Readers tracking that convergence can follow developments at [humanoidintel.ai](https://humanoidintel.ai).

---

## Skeptical Read: How Much Will Actually Get Done by 2028?

The 40-standard target is ambitious for any two-year window, particularly in a field where core technical routes — intracortical vs. ECoG vs. [endovascular](https://bciintel.com/glossary/endovascular), fully implanted vs. transcutaneous — have not converged. Standards work best when there is technical consensus to codify. When there is not, standards either get written too broadly to be useful, or they effectively pick winners among competing technical approaches, which generates its own political resistance.

The draft documents are currently in public comment phase. How much they change between draft and final publication, and how aggressively MIIT enforces implementation timelines across more than 100 enterprises, will determine whether this is genuine industrial architecture-building or a signaling exercise for international standards bodies.

The 2028 deadline also predates meaningful large-scale clinical deployment of most BCI systems globally. Setting standards before clinical evidence has consolidated the technical requirements is a known risk — standards can inadvertently freeze suboptimal solutions or create compliance burdens that slow clinical translation.

---

## Key Takeaways

- China's MIIT released draft BCI standards guidelines on August 25, 2026, targeting more than 40 standards developed or revised by 2028, plus participation in more than 10 international standards.
- The humanoid robot companion document targets at least 100 key standards covering more than 200 enterprises; the BCI framework covers more than 100 enterprises.
- The BCI standard system spans seven domains including hardware, software/algorithms, data/communication, and safety/governance — the exact layers where current commercial BCI platforms are most architecturally divergent.
- The strategic risk for Western developers: patented technical solutions embedded in Chinese national standards can become standard essential patents, creating royalty exposure across entire industrial chains.
- The standards push is happening before BCI technical routes have converged clinically, which risks encoding suboptimal solutions or picking commercial winners by regulatory fiat.
- Western BCI companies have limited direct input into the MIIT process and move slower in international standards bodies — the competitive window is narrow.

---

## Frequently Asked Questions

**What are China's 2026 BCI standardization guidelines?**
On August 25, 2026, China's Ministry of Industry and Information Technology released draft guidelines for a national BCI industry standard system, targeting development or revision of more than 40 BCI standards by 2028 and participation in more than 10 international standards. The guidelines cover hardware, software, data communication, safety, and governance across more than 100 enterprises.

**What is a standard essential patent (SEP) and why does it matter for BCI?**
A standard essential patent is a patent covering a technical solution that becomes mandatory when implementing an industry standard. In BCI, if a national or international standard mandates a specific neural signal data format or communication protocol, any company holding patents on that technology can require licensing fees from all standard-compliant manufacturers — giving early patent holders structural leverage over an entire industry.

**How does China's BCI standards push affect US and European companies?**
Western BCI developers have limited direct input into China's MIIT process. If Chinese national standards are pushed into ISO or IEC international working groups, Chinese stakeholders arrive with an already-developed national standard as their position. US and European companies wanting to sell in China or compete in international markets may need to conform to technical architectures they had no role in designing.

**Will the 40-standard target actually be met by 2028?**
The timeline is aggressive relative to the current state of BCI technical consensus. Standards work best when codifying existing convergence; BCI electrode types, signal acquisition methods, and decoding architectures remain fragmented. The draft is currently in public comment, and its final form and enforcement rigor remain to be seen.

**What BCI technical layers are most exposed to standardization-driven patent risk?**
Based on the MIIT draft's seven-domain structure, the highest-risk layers are data and communication (neural signal formats, transmission protocols, device interoperability) and hardware (electrode array interfaces, signal acquisition specifications) — the same layers where current commercial platforms differ most and where interface compatibility is most commercially necessary.